AstraZeneca COPD drug tozorakimab shows benefits across patient groups
AstraZeneca said tozorakimab for chronic obstructive pulmonary disease showed benefits across a broad patient population in late-stage clinical trials, supporting its expectation of multibillion-dollar sales.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.